Skip to navigation, content
The Leading Practitioners' Resource for Product & Technology Development
92 Crescent Street. Waltham, MA 02453 Tel: 800-338-2223 or 781-891-8080
A presentation by David M. Stout, Ph.D., Director, Global Basic & Pre-clinical Sourcing, Merck Research Laboratories
The pharmaceutical industry is renowned for the complexity of its development process, its risky projects, and its low-yield product pipeline. With increasing pressures on the industry, many of the so-called “Big Pharma” firms have decided that they can’t afford not to outsource non-core activities. One example is Merck & Co., Inc., which has forged a mutually successful partnership with China-based WuXi PharmaTech, a Contract Research Organization with less than ten years in the field. This presentation details the development of Merck’s partnership with a supporting Chinese firm and how that relationship slowly evolved to greater degrees of trust and commitment. It first presents an overview of the drug discovery process and provides a rationale for outsourcing in general – and outsourcing to China in particular. The presentation discusses the business criteria used to assess partners and then recounts the case history of the projects Merck has engaged in with WuXi. Recently, these projects have included FTEs dedicated to Merck and the development of a site dedicated to Merck projects at WuXi’s Shanghai location.
(21 pages)
Now you can try FastTrack for yourself. For just $89, you can access everything on FastTrack for 6 weeks. At the end of your introductory membership, you can renew your membership for a full year at the regular rate of $495 per year. If you're not 100% satisfied with your membership, simply contact us to receive a full refund!
OPTION 1 |
OPTION 2 |
OPTION 3
|
|
To purchase access by phone:
Call 1-800-338-2223 or 781-891-8080 (9:00am - 5:30pm EST)